Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Summit opens new front for ivonescimab, challenging durvalumab after chemoradiation in lung cancer

Summit Therapeutics has begun a late-stage trial pitting its lead drug against durvalumab in unresectable Stage III lung cancer, but has not disclosed size, dosing or timelines.

18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news

Summit Therapeutics has started a third-party-comparator trial for its lead asset: on 18 November 2026 it announced the launch of HARMONi-10, a Phase III study that sets ivonescimab directly against durvalumab in patients with unresectable, locally advanced Stage III non-small cell lung cancer. The company says the study could be used to support registration.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Summit Therapeutics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →